Cardiomyopathy Trial, Recruiting (NCT05209776)

Cardiomyopathy Trial, Recruiting NCT05209776 Sponsor: University Hospital, Toulouse Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT05209776 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Here is the eligibility information in plain English:

Who might be able to join this trial:

(For the main study group) People who have been diagnosed with a specific heart condition called arrhythmogenic right ventricular dysplasia (a disease affecting the right side of the heart's pumping chambers) and are scheduled for a heart electrical mapping procedure
(For the comparison group) People who are scheduled for a heart procedure to correct an abnormal electrical pathway or a type of irregular heartbeat (atrial flutter), and who otherwise have a healthy heart

Who may not be able to join:

People who have been diagnosed with a long-term (chronic) inflammatory disease that affects the whole body
People who have, or are suspected of having, heart involvement caused by an inflammatory disease, or who have an active or ongoing infection of any kind
People who are currently taking medications that suppress or alter the immune system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Philippe MAURY, MD, University Hospital, Toulouse

Phone: 5 61 32 34 70

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05209776

Sponsor: University Hospital, Toulouse

Phase: Not Applicable

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: 5 61 32 34 70

More information: https://clinicaltrials.gov/study/NCT05209776

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Here is the eligibility information in plain English:

Who might be able to join this trial:

(For the main study group) People who have been diagnosed with a specific heart condition called arrhythmogenic right ventricular dysplasia (a disease affecting the right side of the heart's pumping chambers) and are scheduled for a heart electrical mapping procedure
(For the comparison group) People who are scheduled for a heart procedure to correct an abnormal electrical pathway or a type of irregular heartbeat (atrial flutter), and who otherwise have a healthy heart

Who may not be able to join:

People who have been diagnosed with a long-term (chronic) inflammatory disease that affects the whole body
People who have, or are suspected of having, heart involvement caused by an inflammatory disease, or who have an active or ongoing infection of any kind
People who are currently taking medications that suppress or alter the immune system

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Toulouse

Registry

ClinicalTrials.gov

Start date

1 February 2022

Est. completion

1 February 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Identify the inflammatory components by C-reactive protein; Identify the inflammatory components by interleukine1; Identify the inflammatory components by onterleukine6; Identify the inflammatory components by interleukine10; Identify the inflammatory components by Tumor Necrosis Factor; Identify the inflammatory components by Transforming Growth Factor

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov